Nivestim 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
IB/0072 
C.I.z - Changes (Safety/Efficacy) of Human and 
22/05/2023 
PL 
Veterinary Medicinal Products - Other variation 
IB/0071 
C.I.2.a - Change in the SPC, Labelling or PL of a 
12/01/2023 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
SmPC, 
Labelling and 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
product - Implementation of change(s) for which NO 
PL 
new additional data is required to be submitted by 
the MAH 
II/0070/G 
This was an application for a group of variations. 
15/12/2022 
n/a 
B.I.a.1.k - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - New 
storage site of MCB and/or WCB 
B.I.a.1.j - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS -  
Replacement or addition of a site where batch 
control/testing takes place and any of the test 
method at the site is a biol/immunol method 
B.I.a.1.a - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
proposed manufacturer is part of the same 
pharmaceutical group as the currently approved 
manufacturer 
A.7 - Administrative change - Deletion of 
manufacturing sites 
N/0069 
Minor change in labelling or package leaflet not 
22/09/2022 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0068 
C.I.11.z - Introduction of, or change(s) to, the 
15/09/2022 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
PSUSA/1391/
Periodic Safety Update EU Single assessment - 
05/05/2022 
n/a 
PRAC Recommendation - maintenance 
202109 
filgrastim 
Page 2/22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0067/G 
This was an application for a group of variations. 
05/04/2022 
n/a 
B.II.f.1.e - Stability of FP - Change to an approved 
stability protocol 
B.II.f.1.e - Stability of FP - Change to an approved 
stability protocol 
B.I.d.1.c - Stability of AS - Change in the re-test 
period/storage period or storage conditions - Change 
to an approved stability protocol 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.II.f.1.e - Stability of FP - Change to an approved 
stability protocol 
IA/0066/G 
This was an application for a group of variations. 
07/02/2022 
n/a 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
A.7 - Administrative change - Deletion of 
manufacturing sites 
A.7 - Administrative change - Deletion of 
manufacturing sites 
Page 3/22 
 
 
 
 
 
 
 
 
 
 
 
 
 
N/0064 
Minor change in labelling or package leaflet not 
01/10/2021 
PL 
connected with the SPC (Art. 61.3 Notification) 
II/0063 
Submission of an updated RMP version 10.1 in order 
30/09/2021 
n/a 
to update the RMP in accordance with GVP Module V 
and the Guidance on the format of the RMP in the EU 
- in integrated format (Rev. 2.0.1) and to propose 
deletion of selected safety concerns listed as 
important identified risk, important potential risk and 
missing information. 
C.I.11.b - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Implementation of 
change(s) which require to be further substantiated 
by new additional data to be submitted by the MAH 
where significant assessment is required 
N/0062 
Minor change in labelling or package leaflet not 
31/03/2021 
PL 
connected with the SPC (Art. 61.3 Notification) 
II/0061 
Update of section 6.5 of the SmPC to add a 
23/04/2020 
18/11/2020 
SmPC and PL 
Each pre filled syringe is affixed with a needle closed by a 
statement on the content of a derivative of natural 
rubber latex in the needle cover formulation. Section 
6 of the Package Leaflet was updated accordingly. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
needle cover that contains epoxyprene, a derivative of 
natural rubber latex which may come into contact with the 
needle. 
Page 4/22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
II/0059 
B.I.e.2 - Introduction of a post approval change 
26/03/2020 
n/a 
management protocol related to the AS 
IB/0057 
C.I.2.a - Change in the SPC, Labelling or PL of a 
10/12/2019 
18/11/2020 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
II, Labelling 
and PL 
IB/0058/G 
This was an application for a group of variations. 
09/12/2019 
n/a 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.II.d.1.a - Change in the specification parameters 
and/or limits of the finished product - Tightening of 
specification limits 
B.II.d.1.c - Change in the specification parameters 
and/or limits of the finished product - Addition of a 
new specification parameter to the specification with 
its corresponding test method 
B.II.d.1.d - Change in the specification parameters 
and/or limits of the finished product - Deletion of a 
non-significant specification parameter 
B.II.d.1.d - Change in the specification parameters 
and/or limits of the finished product - Deletion of a 
non-significant specification parameter 
B.II.d.1.d - Change in the specification parameters 
Page 5/22 
 
 
 
 
 
 
 
 
 
 
 
 
 
and/or limits of the finished product - Deletion of a 
non-significant specification parameter 
B.II.d.1.d - Change in the specification parameters 
and/or limits of the finished product - Deletion of a 
non-significant specification parameter 
B.II.d.1.d - Change in the specification parameters 
and/or limits of the finished product - Deletion of a 
non-significant specification parameter 
B.II.d.1.z - Change in the specification parameters 
and/or limits of the finished product - Other variation 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure 
(including replacement or addition) 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure 
(including replacement or addition) 
B.II.d.2.e - Change in test procedure for the finished 
product - Update of the test procedure to comply 
with the updated general monograph in the Ph. Eur. 
N/0060 
Minor change in labelling or package leaflet not 
02/12/2019 
18/11/2020 
PL 
connected with the SPC (Art. 61.3 Notification) 
PSUSA/1391/
Periodic Safety Update EU Single assessment - 
16/05/2019 
n/a 
PRAC Recommendation - maintenance 
201809 
filgrastim 
IA/0056/G 
This was an application for a group of variations. 
02/05/2019 
n/a 
B.I.a.4.z - Change to in-process tests or limits 
applied during the manufacture of the AS - Other 
variation 
Page 6/22 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.II.d.1.z - Change in the specification parameters 
and/or limits of the finished product - Other variation 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.e.3.a - Change in test procedure for the 
immediate packaging of the finished product - Minor 
changes to an approved test procedure 
Page 7/22 
 
 
 
 
 
N/0055 
Minor change in labelling or package leaflet not 
12/04/2019 
16/09/2019 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0053 
C.I.2.a - Change in the SPC, Labelling or PL of a 
13/11/2018 
16/09/2019 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
IA/0052/G 
This was an application for a group of variations. 
07/09/2018 
16/09/2019 
Annex II and 
PL 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.I.c.1.z - Change in immediate packaging of the AS 
- Other variation 
B.I.c.2.b - Change in the specification parameters 
and/or limits of the immediate packaging of the AS - 
Addition of a new specification parameter to the 
specification with its corresponding test method 
B.I.c.2.c - Change in the specification parameters 
and/or limits of the immediate packaging of the AS - 
Deletion of a non-significant specification parameter 
(e.g. deletion of an obsolete parameter) 
T/0051 
Transfer of Marketing Authorisation 
06/08/2018 
23/08/2018 
SmPC, 
Page 8/22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Labelling and 
PL 
IB/0050 
C.I.z - Changes (Safety/Efficacy) of Human and 
22/05/2018 
23/08/2018 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
IB/0049 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
24/10/2017 
23/08/2018 
SmPC and PL 
life of the finished product - As packaged for sale 
(supported by real time data) 
IAIN/0048 
B.II.b.2.c.1 - Change to importer, batch release 
20/07/2017 
18/09/2017 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
N/0047 
Minor change in labelling or package leaflet not 
16/02/2017 
18/09/2017 
Labelling and 
connected with the SPC (Art. 61.3 Notification) 
PL 
IB/0046 
C.I.2.a - Change in the SPC, Labelling or PL of a 
11/10/2016 
18/09/2017 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0045 
B.III.2.b - Change to comply with Ph. Eur. or with a 
22/09/2016 
n/a 
national pharmacopoeia of a Member State - Change 
to comply with an update of the relevant monograph 
of the Ph. Eur. or national pharmacopoeia of a 
Member State 
Page 9/22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0044 
B.I.a.2.a - Changes in the manufacturing process of 
01/08/2016 
n/a 
the AS - Minor change in the manufacturing process 
of the AS 
IB/0043/G 
This was an application for a group of variations. 
20/06/2016 
n/a 
B.II.d.1.a - Change in the specification parameters 
and/or limits of the finished product - Tightening of 
specification limits 
B.II.d.1.a - Change in the specification parameters 
and/or limits of the finished product - Tightening of 
specification limits 
B.II.d.1.a - Change in the specification parameters 
and/or limits of the finished product - Tightening of 
specification limits 
B.II.d.1.a - Change in the specification parameters 
and/or limits of the finished product - Tightening of 
specification limits 
N/0042 
Minor change in labelling or package leaflet not 
17/06/2016 
06/07/2016 
PL 
connected with the SPC (Art. 61.3 Notification) 
IG/0693 
B.II.b.1.a - Replacement or addition of a 
02/06/2016 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
PSUSA/1391/
Periodic Safety Update EU Single assessment - 
13/05/2016 
n/a 
PRAC Recommendation - maintenance 
201509 
filgrastim 
IB/0040 
B.I.b.1.z - Change in the specification parameters 
29/02/2016 
n/a 
and/or limits of an AS, starting 
Page 10/22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
material/intermediate/reagent - Other variation 
IB/0038 
B.I.d.1.c - Stability of AS - Change in the re-test 
07/01/2016 
n/a 
period/storage period or storage conditions - Change 
to an approved stability protocol 
IB/0036 
B.II.b.2.a - Change to importer, batch release 
22/12/2015 
n/a 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
IG/0645 
C.I.8.a - Introduction of or changes to a summary of 
17/12/2015 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
II/0033 
C.I.11.b - Introduction of, or change(s) to, the 
24/09/2015 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Implementation of 
change(s) which require to be further substantiated 
by new additional data to be submitted by the MAH 
where significant assessment is required 
IAIN/0035/G 
This was an application for a group of variations. 
14/08/2015 
06/07/2016 
SmPC, 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
Labelling and 
PL 
Page 11/22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
IAIN/0034 
B.II.e.5.a.1 - Change in pack size of the finished 
14/08/2015 
06/07/2016 
SmPC, 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
Labelling and 
PL 
IAIN/0032 
A.1 - Administrative change - Change in the name 
16/07/2015 
06/07/2016 
SmPC, 
and/or address of the MAH 
Labelling and 
PL 
II/0029 
B.I.a.4.e - Change to in-process tests or limits 
02/07/2015 
n/a 
applied during the manufacture of the AS - Deletion 
of an in-process test which may have a significant 
effect on the overall quality of the AS 
II/0028/G 
This was an application for a group of variations. 
02/07/2015 
n/a 
B.I.b.1.e - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a 
specification parameter which may have a significant 
effect on the overall quality of the AS and/or the FP 
B.I.b.1.e - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a 
specification parameter which may have a significant 
effect on the overall quality of the AS and/or the FP 
R/0025 
Renewal of the marketing authorisation. 
26/03/2015 
27/05/2015 
SmPC, 
Based on the review of data on quality, safety and efficacy, 
Labelling and 
including all variations introduced since the marketing 
Page 12/22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PL 
authorisation was granted, the CHMP considered that the 
benefit-risk balance of Nivestim in the approved indications 
remains favourable and therefore recommended the 
renewal of the marketing authorisation with unlimited 
validity. 
IG/0555 
C.I.8.a - Introduction of or changes to a summary of 
22/05/2015 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
N/0027 
Minor change in labelling or package leaflet not 
05/01/2015 
27/05/2015 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0026/G 
This was an application for a group of variations. 
05/12/2014 
n/a 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.III.2.a.1 - Change of specification(s) of a former 
non EU Pharmacopoeial substance to fully comply 
with the Ph. Eur. or with a national pharmacopoeia of 
a Member State - AS 
II/0022 
B.I.b.2.d - Change in test procedure for AS or 
25/09/2014 
n/a 
starting material/reagent/intermediate - Substantial 
change to or replacement of a 
biological/immunological/immunochemical test 
method or a method using a biological reagent for a 
Page 13/22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
biological AS 
IG/0477 
C.I.8.a - Introduction of or changes to a summary of 
03/09/2014 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
IA/0023/G 
This was an application for a group of variations. 
01/08/2014 
15/01/2015 
Annex II and 
PL 
A.7 - Administrative change - Deletion of 
manufacturing sites 
A.7 - Administrative change - Deletion of 
manufacturing sites 
A.7 - Administrative change - Deletion of 
manufacturing sites 
A.7 - Administrative change - Deletion of 
manufacturing sites 
A.7 - Administrative change - Deletion of 
manufacturing sites 
IB/0021/G 
This was an application for a group of variations. 
16/04/2014 
n/a 
B.I.a.1.k - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - New 
storage site of MCB and/or WCB 
B.I.a.1.k - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - New 
storage site of MCB and/or WCB 
IB/0019 
C.I.2.a - Change in the SPC, Labelling or PL of a 
21/01/2014 
15/01/2015 
SmPC and PL 
generic/hybrid/biosimilar products following 
Page 14/22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IG/0382 
C.I.8.a - Introduction of or changes to a summary of 
02/12/2013 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
IB/0018 
B.I.a.1.f - Change in the manufacturer of AS or of a 
29/10/2013 
n/a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
N/0017 
Minor change in labelling or package leaflet not 
07/08/2013 
18/12/2013 
PL 
connected with the SPC (Art. 61.3 Notification) 
IG/0317 
C.I.z - Changes (Safety/Efficacy) of Human and 
23/07/2013 
n/a 
Veterinary Medicinal Products - Other variation 
II/0014/G 
This was an application for a group of variations. 
25/04/2013 
n/a 
B.II.b.1.c - Addition of a new site for manufacture, 
primary packaging and release testing of the finished 
product. 
B.II.b.4.c - Increase in the batch size for the finished 
product. 
B.II.e.1.a.3 - Change to the material used for the 
needle shield.  
Page 15/22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.II.b.2.a - Addition of a new release and stability 
testing site for the finished product. 
A.5.b - Change in the address of a site registered for 
secondary packaging of the finished product. 
A.7 - Deletion of a secondary packaging site. 
B.II.b.1.c - Replacement or addition of a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch 
release, batch control, and secondary packaging, for 
biological/immunological medicinal products. 
B.II.b.4.c - Change in the batch size (including batch 
size ranges) of the finished product - The change 
requires assessment of the comparability of a 
biological/immunological medicinal product 
B.II.e.1.a.3 - Change in immediate packaging of the 
finished product - Qualitative and quantitative 
composition - Sterile medicinal products and 
biological/immunological medicinal products 
B.II.b.2.a - Change to batch release arrangements 
and quality control testing of the FP - Replacement 
or addition of a site where batch control/testing 
takes place 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer of the finished 
product, including quality control sites (excluding 
manufacturer for batch release) 
A.7 - Administrative change - Deletion of 
manufacturing sites 
II/0013/G 
This was an application for a group of variations. 
25/04/2013 
18/12/2013 
Annex II 
Page 16/22 
 
 
 
 
 
 
 
 
B.I.a.1.e – Addition of Hospira Zagreb d.o.o, 
Prudnička cesta 60, 10291 Prigorje Brdovečko, 
Croatia, for manufacture and quality control of the 
active substance. 
B.I.a.1.f – Registration of new sites for testing of 
master and working cell banks.  
B.I.a.2.c – Changes to the manufacturing process of 
the active substance. 
B.I.a.3.c – Increase in the batch size of the active 
substance manufacture. 
B.I.a.4.a – Tightening of an in-process test 
specification. 
B.I.a.4.b – Addition of new in-process tests. 
B.I.a.4.z – Reclassification of in-process tests.  
B.I.b.1.d – Deletion of  tests from the specifications 
for the inclusion bodies.  
B.I.c.1.b – A new container closure system is 
proposed for storage of the active substance. 
B.I.a.1.e - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
change relates to a biological AS or a starting 
material [-] used in the manufacture of a 
biological/immunological product 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
B.I.a.2.c - Changes in the manufacturing process of 
the AS - The change refers to a [-] substance in the 
Page 17/22 
 
 
 
 
 
 
 
manufacture of a biological/immunological medicinal 
product and is not related to a protocol 
B.I.a.3.c - Change in batch size (including batch size 
ranges) of AS or intermediate - The change requires 
assessment of the comparability of a 
biological/immunological AS 
B.I.a.4.a - Change to in-process tests or limits 
applied during the manufacture of the AS - 
Tightening of in-process limits 
B.I.a.4.b - Change to in-process tests or limits 
applied during the manufacture of the AS - Addition 
of a new in-process test and limits 
B.I.a.4.z - Change to in-process tests or limits 
applied during the manufacture of the AS - Other 
variation 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.I.c.1.b - Change in immediate packaging of the AS 
- Qualitative and/or quantitative composition for 
sterile and non-frozen biological/immunological ASs 
IG/0286 
C.I.z - Changes (Safety/Efficacy) of Human and 
12/04/2013 
n/a 
Veterinary Medicinal Products - Other variation 
II/0011 
Update of section 4.8 of the SmPC as per the 
13/12/2012 
18/12/2013 
SmPC, Annex 
The MAH aligned the product information of Nivestim with 
reference medicinal product (Neupogen, Amgen 
Europe BV.) and in accordance with the Hospira 
global Core Safety Information. Angiopathy and 
II, Labelling 
the current safety information of the reference medicinal 
and PL 
product Neupogen. No cases of pseudogout and angiopathy 
were retrieved from the safety database. 
Page 18/22 
 
 
 
 
 
 
 
 
 
information relating to pseudogout have been added 
and the term, " decreased glucose"  has been 
amended to "blood glucose decreased" in-line with 
the reference product. A minor editorial correction 
was also included.  The PL has also been updated 
accordingly.  
In addition, the MAH took the opportunity to update 
the list of local representatives in the PL. 
Furthermore, the PI is being brought in line with the 
latest QRD template version 8.2. 
C.I.2.b - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Change(s) require to be further 
substantiated by new additional data to be submitted 
by the MAH 
IB/0012 
B.I.b.1.b - Change in the specification parameters 
18/10/2012 
n/a 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
IAIN/0010 
B.II.b.1.a - Replacement or addition of a 
23/07/2012 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IB/0009 
B.I.a.1.f - Change in the manufacturer of AS or of a 
18/07/2012 
n/a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
Page 19/22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
batch control/testing takes place 
IAIN/0007 
B.II.b.1.a - Replacement or addition of a 
04/05/2012 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IAIN/0008/G 
This was an application for a group of variations. 
18/04/2012 
n/a 
C.I.9.a - Changes to an existing pharmacovigilance 
system as described in the DDPS - Change in the 
QPPV 
C.I.9.c - Changes to an existing pharmacovigilance 
system as described in the DDPS - Change of the 
back-up procedure of the QPPV 
C.I.9.e - Changes to an existing pharmacovigilance 
system as described in the DDPS - Changes in the 
major contractual arrangements with other persons 
or organisations involved in the fulfilment of 
pharmacovigilance obligations and described in the 
DD 
C.I.9.g - Changes to an existing pharmacovigilance 
system as described in the DDPS - Change of the site 
undertaking pharmacovigilance activities 
C.I.9.h - Changes to an existing pharmacovigilance 
system as described in the DDPS - Other change(s) 
to the DDPS that does not impact on the operation of 
the pharmacovigilance system 
IB/0006 
B.I.b.2.e - Change in test procedure for AS or 
20/01/2012 
n/a 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
Page 20/22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
or addition) for the AS or a starting 
material/intermediate 
IAIN/0005/G 
This was an application for a group of variations. 
23/11/2011 
14/06/2012 
Annex II and 
PL 
B.II.b.2.b.1 - Change to batch release arrangements 
and quality control testing of the FP - Not including 
batch control/testing 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer of the finished 
product, including quality control sites (excluding 
manufacturer for batch release) 
N/0004 
Following the CHMP request, the MAH applied to 
25/07/2011 
14/06/2012 
PL 
update section 4 of package leaflet to include 
warnings with respect to reports of graft versus host 
disease (GvHD) and fatalities. In addition, user 
instructions in package leaflet have been changed to 
align with wording used by biological product 
(Neupogen) and to address concerns around the 
potential for loss/waste of product. Finally, the MAH 
took this opportunity to update the contact details 
for Czech, Estonian, Hungarian, Irish, Latvian, 
Lithuanian, Polish and Slovenian local 
representatives. 
Minor change in labelling or package leaflet not 
connected with the SPC (Art. 61.3 Notification) 
IB/0003 
To extend the maximum out of refrigerator storage 
19/11/2010 
n/a 
SmPC and PL 
period for Nivestim from 48 hours to 7 days based 
Page 21/22 
 
 
 
 
 
 
 
 
 
 
 
 
 
on real-time data. 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
life of the finished product - As packaged for sale 
(supported by real time data) 
IB/0002 
To extend the shelf-life for the 12 MU/0.2 ml and 30 
19/10/2010 
n/a 
SmPC 
MU/0.5 ml presentations from 2 years to 30 months 
based on real-time stability data. The shelf-life for 
the 48 MU/0.5 ml presentation is currently 30 
months and will remain unchanged. 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
life of the finished product - As packaged for sale 
(supported by real time data) 
IA/0001 
To change the plunger rods and safety device for 
14/07/2010 
n/a 
SmPC and PL 
Nivestim 30MU and 48MU. 
B.II.e.6.a - Change in any part of the (primary) 
packaging material not in contact with the finished 
product formulation - Change that affects the 
product information 
Page 22/22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
